# Delve Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delve-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.delve.bio
- Total disclosed funding: $36M
- Latest round: Series A (Jan 3, 2023)
- Investors on record: 3

## About

Based in California, US, and founded in 2022, Delve Bio Inc. enables single-shot, pathogen-neutral detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). The company was founded by Brad Murray, who is leading the firm as CEO as of 2023. In June 2023, the firm raised USD 35 million in Series A funding led by investor Perceptive Xontogeny Venture Funds   with participation from investors Section 32 and Google Ventures.

The company offers molecular insights for the precision care of patients by giving a single shot pathogen-unbiased, pathogen-agnostic detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). It uses mNGS to give labs and physicians the information they need to diagnose both common and uncommon infectious disorders.

The company plans to use the June 2023 funding to market its metagenomic next-generation sequencing (mNGS)-based infectious disease test.

## Funding rounds

- Series A, Jan 3, 2023, $36M — GV, Perceptive Advisors, Section 32

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A